Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide

Abstract Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs. Because darolutamide has a distinct chemical structure to ot...

Full description

Saved in:
Bibliographic Details
Main Authors: Saizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, Mamoru Hamaguchi, Ken Kuwahara, Mamoru Hashimoto, Shogo Adomi, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Hirotsugu Uemura
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
apalutamide
ARAT
darolutamide
enzalutamide
nmCRPC
prostate cancer
Online Access:https://doi.org/10.1002/cam4.5189
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.5189

Similar Items